The decrease in breast cancer mortality is the result of major therapeutic advances (hormone therapy, taxanes, and anti-Her2 targeted therapy) associated with an increase in the proportion of cancers diagnosed at an early stage, notably through organized screening. The gene discussed is ERBB2; the disease is breast carcinoma.